UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 203

Sortiert nach

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients

PloS one, 2015-08, Vol.10 (8), p.e0134395

2015

Volltextzugriff (PDF)

Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients

The Journal of infectious diseases, 2018-06, Vol.218 (1), p.114-123

2018

Volltextzugriff (PDF)

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants

Hepatology (Baltimore, Md.), 2019-09, Vol.70 (3), p.771-787

2019

Volltextzugriff (PDF)

Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids

Frontiers in immunology, 2018-04, Vol.9, p.723-723

2018

Volltextzugriff (PDF)

Treatment and re-treatment results of HCV patients in the DAA era

PloS one, 2020-05, Vol.15 (5), p.e0232773-e0232773

2020

Volltextzugriff (PDF)

Therapeutic preparedness: DAA-resistant HCV variants in vitro and in vivo

Hepatology (Baltimore, Md.), 2023-08, Vol.78 (2), p.385-387

2023

Volltextzugriff (PDF)

Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells

PLoS pathogens, 2011-05, Vol.7 (5), p.e1002045-e1002045

2011

Volltextzugriff (PDF)

Hepatitis C “true” late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy

Journal of hepatology, 2017-04, Vol.66 (4), p.862-863

2017

Volltextzugriff (PDF)

Lightweight Techniques to Improve Generalization and Robustness of U-Net Based Networks for Pulmonary Lobe Segmentation

Bioengineering (Basel), 2024-01, Vol.11 (1), p.21

2024

Volltextzugriff (PDF)

Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2018-07, Vol.24 (7), p.524-530

2018

Volltextzugriff (PDF)

Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure

JHEP reports, 2024-03, Vol.6 (3), p.100994-100994, Article 100994

2024

Volltextzugriff (PDF)

Reply to: “Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings”

Journal of hepatology, 2021-07, Vol.75 (1), p.254-255

2021

Volltextzugriff (PDF)

Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy

PloS one, 2019-11, Vol.14 (11), p.e0224751-e0224751

2019

Volltextzugriff (PDF)

SHARED: An International Collaboration to Unravel Hepatitis C Resistance

Viruses, 2021-08, Vol.13 (8), p.1580

2021

Volltextzugriff (PDF)

Hepatic sarcoidosis: Clinical characteristics and outcome

JHEP reports, 2021-12, Vol.3 (6), p.100360-100360, Article 100360

2021

Volltextzugriff (PDF)

Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis

Journal of clinical medicine, 2020-09, Vol.9 (9), p.2702

2020

Volltextzugriff (PDF)

Persistence of HCV in Acutely-Infected Patients Depletes C24-Ceramide and Upregulates Sphingosine and Sphinganine Serum Levels

International journal of molecular sciences, 2016-06, Vol.17 (6), p.922-922

2016

Volltextzugriff (PDF)

Is Olfactory Testing a Useful Diagnostic Tool to Identify SARS-CoV-2 Infections Early? A Cross-Sectional and Longitudinal Analysis

Journal of clinical medicine, 2023-04, Vol.12 (9), p.3162

2023

Volltextzugriff (PDF)

Primary Biliary Cholangitis (PBC)-Autoimmune Hepatitis (AIH) Variant Syndrome: Clinical Features, Response to Therapy and Long-Term Outcome

Journal of clinical medicine, 2023-11, Vol.12 (22), p.7047

2023

Volltextzugriff (PDF)

Expanding epidemic of recently acquired HCV in HIV-coinfected patients over a period of 10 years

JHEP reports, 2023-07, Vol.5 (7), p.100701-100701, Article 100701

2023

Volltextzugriff (PDF)

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillarassociated protein 4 in hepatitis C patients

Clinical and Molecular Hepatology, 2019, 25(1), , pp.42-51

2019

Volltextzugriff (PDF)

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients

Clinical and molecular hepatology, 2019-03, Vol.25 (1), p.42-51

2019

Volltextzugriff (PDF)

Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy

PloS one, 2016-06, Vol.11 (6), p.e0156731-e0156731

2016

Volltextzugriff (PDF)

Exploring the future of Kafue National Park, Zambia: Scenario-based land use and land cover modelling to understand drivers and impacts of deforestation

Land use policy, 2023-03, Vol.126, p.106535, Article 106535

2023

Volltextzugriff (PDF)

1 – 25 von 203

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(173)
Mit Volltextzugriff
(184)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(187)
Japanisch
(19)
Deutsch
(14)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients

Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants

Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids

Treatment and re-treatment results of HCV patients in the DAA era

Therapeutic preparedness: DAA-resistant HCV variants in vitro and in vivo

Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells

Hepatitis C “true” late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy

Lightweight Techniques to Improve Generalization and Robustness of U-Net Based Networks for Pulmonary Lobe Segmentation

Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients

Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure

Reply to: “Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings”

Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy

SHARED: An International Collaboration to Unravel Hepatitis C Resistance

Hepatic sarcoidosis: Clinical characteristics and outcome

Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis

Persistence of HCV in Acutely-Infected Patients Depletes C24-Ceramide and Upregulates Sphingosine and Sphinganine Serum Levels

Is Olfactory Testing a Useful Diagnostic Tool to Identify SARS-CoV-2 Infections Early? A Cross-Sectional and Longitudinal Analysis

Primary Biliary Cholangitis (PBC)-Autoimmune Hepatitis (AIH) Variant Syndrome: Clinical Features, Response to Therapy and Long-Term Outcome

Expanding epidemic of recently acquired HCV in HIV-coinfected patients over a period of 10 years

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillarassociated protein 4 in hepatitis C patients

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients

Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy

Exploring the future of Kafue National Park, Zambia: Scenario-based land use and land cover modelling to understand drivers and impacts of deforestation

Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers

Suchergebnisse filtern